Welcome to our dedicated page for Crispr Therapeut SEC filings (Ticker: CRSP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
CRISPR Therapeutics AG filings document operating results, pipeline disclosures and capital-structure matters for a Swiss biopharmaceutical company developing gene-based medicines. Form 8-K reports furnish quarterly and annual financial results, business highlights for CASGEVY and investigational programs, clinical and regulatory updates across cardiovascular, autoimmune, immuno-oncology and regenerative medicine, and material-event disclosures.
The filing record also includes proxy materials covering shareholder voting and executive compensation, shelf-registration and prospectus-supplement disclosures for common-share offerings, and material definitive agreements for convertible senior notes due 2031. These filings describe common shares, equity financing mechanics, debt terms, governance matters and business disclosures tied to the company’s CRISPR/Cas9, LNP, CAR-T and siRNA platforms.
CRISPR Therapeutics reported the results of its June 4, 2026 annual shareholder meeting, where all management proposals were approved. Shareholders adopted the new 2026 Stock Option and Incentive Plan, which replaces and rolls forward remaining capacity from earlier equity plans.
They also approved amendments to the company’s Swiss articles of association, including an increase to the capital band and an increase to conditional share capital for potential conversion of bonds and similar instruments. The meeting re-elected all eleven directors, four Compensation Committee members, the independent voting rights representative, and Ernst & Young entities as Swiss statutory auditor and U.S. registered public accounting firm.
Shareholders approved the 2025 financial statements, carried forward the net loss, discharged the Board and Executive Committee from liability for 2025 activities, and backed both Swiss and U.S.-style executive compensation votes, including multiple binding decisions on director and executive pay and equity grants.
KASINGER JAMES R. reported acquisition or exercise transactions in this Form 4 filing.
CRISPR Therapeutics AG reported that its General Counsel and Secretary, James R. Kasinger, received a grant of 17,000 restricted stock units. Each unit represents a right to receive one common share. All 17,000 units are scheduled to vest on November 29, 2028, if the vesting conditions are met.
Patel Naimish reported acquisition or exercise transactions in this Form 4 filing.
CRISPR Therapeutics AG reported that Chief Medical Officer Naimish Patel received a grant of 22,000 restricted stock units. Each unit represents one common share. The award was granted as compensation on May 29, 2026, and all 22,000 units are scheduled to vest on November 29, 2028, subject to the usual conditions.
Prasad Raju reported acquisition or exercise transactions in this Form 4 filing.
CRISPR Therapeutics AG reported that its Chief Financial Officer, Prasad Raju, received a grant of 19,500 Restricted Stock Units on May 29, 2026. Each RSU represents a contingent right to receive one common share, so this award ties directly to future share ownership.
All 19,500 underlying common shares will vest in a single tranche on November 29, 2028, aligning the CFO’s compensation with the company’s long-term performance. Following this grant, the filing shows 19,500 derivative securities linked to common shares held directly.
CRISPR Therapeutics AG Chief Medical Officer Naimish Patel reported RSU vesting and a related share sale. On May 28, 10,000 Restricted Stock Units converted into 10,000 Common Shares at $0.00 per share. On May 29, 3,786 Common Shares were sold at $55.62 per share to cover tax withholding, as mandated by the company’s RSU Settlement Policy and described as non-discretionary. Following these transactions, Patel directly held 19,357 Common Shares. The underlying RSU award covers 40,000 shares, with 10,000-share tranches scheduled to vest annually from 2025 through 2028.
CRISPR Therapeutics reporting persons Orbis Investment Management Ltd and Allan Gray Australia Pty Ltd filed an Amendment No. 2 to a Schedule 13G/A disclosing beneficial ownership. The filing shows 6,106,011 shares beneficially owned in total, representing 6.3% of common stock. Orbis holds 6,090,194 shares with sole voting and dispositive power; Allan Gray holds 15,817 shares with sole voting and dispositive power. The filing states these Reporting Persons are classified as non-U.S. institutions equivalent to an investment adviser and includes a certification regarding foreign regulatory comparability.
CRISPR Therapeutics AG reports a Schedule 13G filing showing Capital World Investors beneficially owns 4,929,428 shares of Common Stock, equal to 5.1% of the company.
The filing states CWI has sole voting power over 4,897,705 shares and sole dispositive power over 4,929,428 shares. The ownership figure is stated as of 03/31/2026.
CRISPR Therapeutics’ Q1 2026 report shows it remains a late‑stage R&D company with substantial cash and a larger capital base. Total revenue was modest at $1.5 million, while operating expenses reached $131.7 million, driven mainly by $68.6 million in research and development and $45.9 million of collaboration expense under its Vertex hemoglobinopathy agreements.
The company reported a net loss of $122.9 million, slightly improved from $136.0 million a year earlier, with basic and diluted loss per share of $1.28 on 96.1 million weighted‑average shares. Operating cash outflow was $108.9 million, partly offset by strong financing inflows.
Liquidity remains a key strength. As of March 31 2026, cash, cash equivalents and marketable securities totaled about $2.44 billion, within total assets of $2.73 billion. During the quarter CRISPR issued $600 million of Convertible Senior Notes due 2031 at a 1.7308% coupon, creating $585.5 million of long‑term debt and net proceeds of about $585.4 million. The added capital supports continued investment across its CASGEVY hemoglobinopathy franchise, in vivo liver programs such as CTX310, siRNA collaboration asset CTX611 and next‑generation CAR‑T candidate zugo‑cel.
CRISPR Therapeutics reported first quarter 2026 results that combine early commercial revenue from CASGEVY with a still-sizeable net loss and a much stronger cash position.
CASGEVY, its gene-edited therapy for sickle cell disease and transfusion-dependent beta thalassemia, generated $43 million in first quarter 2026 revenue. More than 500 people worldwide have initiated treatment, and regulators have approved CASGEVY in multiple regions covering over 60,000 eligible patients. Vertex has completed a U.S. regulatory submission to extend use to children ages 5–11, and reimbursement continues to expand in key markets.
Financially, cash, cash equivalents and marketable securities were $2.44 billion as of March 31, 2026, up from $1.98 billion at year-end, mainly from $585.4 million in net proceeds from convertible senior notes. Research and development expenses were $68.6 million, and general and administrative expenses were $17.2 million, both lower than a year earlier. Net loss narrowed to $122.9 million (basic and diluted net loss per share of $1.28) from $136.0 million in the first quarter of 2025.
Beyond CASGEVY, the company highlighted progress across in vivo liver editing, siRNA programs, the zugo-cel autoimmune and oncology platform, in vivo CAR-T approaches, and its regenerative medicine program in diabetes, underscoring a broad pipeline alongside its first commercial product.
CRISPR Therapeutics reported a Schedule 13G/A showing 11,313,623 shares beneficially owned (representing 11.79% of the common stock). The filing attributes ownership to ARK Investment Management LLC and Catherine D. Wood, with ARK holding 10,545,920 shares of sole voting power and total dispositive power over 11,313,623 shares. The amendment is signed and dated 04/30/2026. The filing notes ARK Innovation ETF as a client holding more than 5% within ARK's client list.